Aprea Therapeutics, Inc.
NCM: APRELive Quote
📈 ZcoreAI Score
Our AI model analyzes Aprea Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get APRE Z-Score →About Aprea Therapeutics, Inc.
Healthcare
Biotechnology
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
📊 Fundamental Analysis
Aprea Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -98.4% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -74.6%, which indicates that capital utilization is currently under pressure.
At a current price of $0.92, APRE currently sits at the 22nd percentile of its 52-week range (Range: $0.55 - $2.22).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$10.50M
Trailing P/E
--
Forward P/E
-1.39
Beta (5Y)
1.57
52W High
$2.22
52W Low
$0.55
Avg Volume
2.38M
Day High
Day Low